Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history

European Journal of Cancer

Volumn 49, Issue 10, 2013, Pages 2303-2310

  Kelly, Claire ^a   Bhuva, Neel ^b   Harrison, Mark ^b   Buckley, Andrew ^c   Saunders, Mark ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c Hospira Ltd   (United Kingdom)

Author keywords

Capecitabine; Cardiotoxicity; Colorectal; Fluorouracil; Raltitrexed

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; GEMCITABINE; LEVOLEUCOVORIN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; RALTITREXED; RECOMBINANT INTERFERON;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CARDIOTOXICITY; CARDIOVASCULAR RISK; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DIGESTIVE SYSTEM CANCER; DRUG TOLERABILITY; ESOPHAGUS CANCER; GALLBLADDER CANCER; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; LUNG CANCER; MEDICAL AUDIT; METASTATIC COLORECTAL CANCER; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER; SYSTEMATIC REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FLUOROURACIL; HEART DISEASES; HUMANS; NEOPLASMS; QUINAZOLINES; RETROSPECTIVE STUDIES; THIOPHENES;

EID: 84878418524     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.03.004     Document Type: Article

References (48)

1. N. Wolmark, H. Rockette, and B. Fisher The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03 J Clin Oncol 11 1993 1879 1887
2. N. Wolmark, H. Rockette, and E. Mamounas Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04 J Clin Oncol 17 1999 3553 3559
3. M.J. O'Connell, J.A. Mailliard, and M.J. Kahn Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer J Clin Oncol 15 1997 246 250
4. M.J. O'Connell, J.A. Laurie, and M. Kahn Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer J Clin Oncol 16 1998 295 300
5. A. Zaniboni Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival J Clin Oncol 15 1997 2432 2441
6. E. Van Cutsem, C. Twelves, and J. Cassidy Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 2001 4097 4106
7. P.M. Hoff, R. Ansari, and G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2001 2282 2292
8. E. Van Cutsem, and J. Oliveira Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl. 4 2009 61 63
9. M.W. Saif, M.M. Shah, and A.R. Shah Fluoropyrimidine-associated cardiotoxicity: revisited Expert Opin Drug Saf 8 2009 191 202
10. C. Schober, E. Papageorgiou, and A. Harstrick Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer Cancer 72 1993 2242 2247
11. N. Meydan, I. Kundak, and T. Yavuzsen Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up Jpn J Clin Oncol 35 2005 265 270
12. A.L. Jackman, G.A. Taylor, and W. Gibson ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study Cancer Res 51 1991 5579 5586
13. D. Cunningham, J.R. Zalcberg, and U. Rath Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group Ann Oncol 7 1996 961 965
14. D. Cunningham Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed) Tumori 83 Suppl. 1 1997 S70 S71
15. G. Cocconi, D. Cunningham, and C.E. Van Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group J Clin Oncol 16 1998 2943 2952
16. R. Pazdur, N.J. Meropol, and E.S. Casper Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer Invest New Drugs 13 1996 355 358
17. I. Popov, A. Carrato, and A. Sobrero Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) Eur J Cancer 44 2008 2204 2211
18. D. Cunningham, J. Zalcberg, and J. Maroun Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials Eur J Cancer 38 2002 478 486
19. Hospira UK Limited. Tomudex summary of product characteristics; 2011.
20. C.E. Paiva, B.S. Paiva, and R. Garita Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer - a case report with a discussion on this clinical dilemma J Gastrointest Cancer 40 2009 133 137
21. F. Gundling, M. Fuchs, and L. Nowak "Iatrogenic acute coronary syndrome" - 59 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil Z Gastroenterol 44 2006 975 979
22. C.H. Köhne, P. Thuss-Patience, and M. Friedrich Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity Br J Cancer 77 1998 973 977
23. C. Kosmas, M.S. Kallistratos, and P. Kopterides Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study J Cancer Res Clin Oncol 134 2008 75 82
24. D. Rossi, P. Alessandroni, and V. Catalano Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer Clin Breast Cancer 7 2007 857 860
25. P. Tsibiribi, J. Descotes, and C. Lombard-Bohas Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease Bull Cancer 93 2006 E27 E30
26. S.A. Jensen, and J.B. Sorensen Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine Cancer Chemother Pharmacol 58 2006 487 493
27. M. Ng, D. Cunningham, and A.R. Norman The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC) Eur J Cancer 41 2005 1542 1546
28. N. Tsavaris, C. Kosmas, and M. Vadiaka 5-Fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study J BUON 10 2005 205 211
29. C. Ceyhan, N. Meydan, and S. Barutca Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion J Clin Pharm Ther 29 2004 267 271
30. A. Wacker, C. Lersch, and U. Scherpinski High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients Oncology 65 2003 108 112
31. N. Tsavaris, C. Kosmas, and M. Vadiaka Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients Med Sci Monit 8 2002 PI51 PI57
32. W.S. Wang, P.M. Chen, and T.J. Chiou Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience Jpn J Clin Oncol 28 1998 16 19
33. C.C. Meyer, K.A. Calis, and L.B. Burke Symptomatic cardiotoxicity associated with 5-fluorouracil Pharmacotherapy 17 1997 729 736
34. T.C. Kok, G.A. van der, and T.A. Splinter 5-Fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group Ann Oncol 7 1996 533 534
35. G.H. Blijham The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer J Infus Chemother 6 1996 114 117
36. Y.H. Bécouarn, R.C. Brunet, and M.L. Rouhier High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer Cancer 76 1995 1126 1131
37. D.L. Keefe, N. Roistacher, and M.K. Pierri Clinical cardiotoxicity of 5-fluorouracil J Clin Pharmacol 33 1993 1060 1070
38. S.S. Akhtar, K.P. Salim, and Z.A. Bano Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study Oncology 50 1993 441 444
39. M. de Forni, M.C. Malet-Martino, and P. Jaillais Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study J Clin Oncol 10 1992 1795 1801
40. W. Gradishar, E. Vokes, R. Schilsky, R. Weichselbaum, and W. Panje Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience Med Pediatr Oncol 19 1991 8 15
41. S.A. Jensen, P. Hasbak, and J. Mortensen Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle J Clin Oncol 28 2010 5280 5286
42. R. Labianca, G. Beretta, and M. Clerici Cardiac toxicity of 5-fluorouracil: a study on 1083 patients Tumori 68 1982 505 510
43. A.M. Grandi, G. Pinotti, and E. Morandi Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study Ann Oncol 8 1997 705 708
44. T. Stewart, N. Pavlakis, and M. Ward Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina Intern Med J 40 2010 303 307
45. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. In: SEER Cancer Statistics Review, 1975-2007. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
46. J.F. Piccirillo, A. Vlahiotis, L.B. Barrett, K.L. Flood, E.L. Spitznagel, and E.W. Steyerberg The changing prevalence of comorbidity across the age spectrum Crit Rev Oncol Hematol 67 2008 124 132
47. M. Bory, F. Pierron, and D. Panagides Coronary artery spasm in patients with normal or near normal coronary arteries. Long-term follow-up of 277 patients Eur Heart J 17 1996 1015 1021
48. NICE Guidance. Colorectal cancer: the diagnosis and management of colorectal cancer; 2011.